Project Grant R01CA316533
Award Date 7/20/26
Completion Date 6/30/31
Dollars Obligated $388K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
- The National Cancer Institute awarded Mayo Clinic $558,016 on May 8, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate accelerated biological aging and immunosenescence as drivers of racial disparities in monoclonal gammopathy of undetermined significance (MGUS). The funded research examines why multiple myeloma and its precursor condition MGUS occur at disproportionately high rates and younger average ages in individuals of African ancestry. The project tests the...
- The National Cancer Institute awarded Mayo Clinic $415,000 on May 14, 2026, under the Cancer Treatment Research program (CFDA 93.395) to improve treatment sensitivity through SYK using novel translational models of uveal melanoma. Performance runs through April 30, 2028, at Mayo Clinic's Rochester, Minnesota facility. This is a project grant supporting development and evaluation of improved cancer treatment methods through laboratory and clinical research, including molecularly targeted...
- The National Cancer Institute awarded Mayo Clinic $685,116 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of interleukin-5 (IL-5) in chimeric antigen receptor T cell immunotherapy for cancer. The project addresses treatment failure and toxicity in CAR T cell therapy, which has achieved FDA approval in relapsed or refractory hematological cancers but shows high relapse rates within two years and significant adverse effects including...
- The National Institutes of Health National Cancer Institute awarded Mayo Clinic $651,290 on August 1, 2026, under the Cancer Treatment Research program (CFDA 93.395, Assistance Listing 93.395) to investigate the regulation of anti-tumor immunity by B7-H3, a protein overexpressed on many tumor types that suppresses immune responses. The research will identify the immune inhibitory receptors through which B7-H3 exerts its immunomodulatory effects during tumor responses, with particular focus on...
- The National Institutes of Health National Cancer Institute awarded $687,314 to Mayo Clinic Jacksonville on July 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate senescence and resistance mechanisms in glioblastoma and to develop combination therapeutic strategies that overcome drug resistance. The funded research examines how glioblastomas develop resistance to mitotic kinase and kinesin inhibitors (ispinesib, alisertib, volasertib, and etoposide) through...
- The National Cancer Institute awarded Mayo Clinic Jacksonville $620,671 on June 23, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and test a bioresorbable implant for local delivery of chemotherapy to aggressive meningiomas. The project addresses treatment limitations in meningioma management. Meningiomas are the most common adult central nervous system tumors, with over 36,000 diagnosed annually in the United States. Current treatment—maximal safe surgical resection...
- The National Cancer Institute awarded Mayo Clinic Arizona $237,660 on December 25, 2025, under the Cancer Research Manpower program (CFDA 93.398) to support research elucidating the functional role of KLRG1-expressing CD4+ T conventional helper cells in the tumor microenvironment and developing a novel immunotherapy to selectively deplete KLRG1-expressing CD4+ T cells. The research investigates how KLRG1+ tumor-infiltrating T cells modify the tumor microenvironment and contribute to immune...
- The National Cancer Institute awarded Mayo Clinic $667,710 on March 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct a randomized Phase 2 trial evaluating blood-based tumor and immune markers for risk stratification and treatment response monitoring in oligometastatic castration-sensitive prostate cancer. The project integrates prostate cancer-derived extracellular vesicles and circulating tumor DNA as blood markers to identify patients who will benefit from...
- The National Cancer Institute awarded Mayo Clinic a cooperative agreement totaling $688,661 on June 9, 2026, to develop and validate cell-free DNA approaches for prospective detection and monitoring of malignant peripheral nerve sheath tumors (MPNST) and their precursor lesions in neurofibromatosis type 1 (NF1) patients under the Cancer Detection and Diagnosis Research program (CFDA 93.394). Mayo Clinic will conduct three integrated research objectives: determining whether integrative...
- The National Institutes of Health National Cancer Institute awarded Mayo Clinic $659,028 on May 20, 2026, under the Cancer Treatment Research program (CFDA 93.395) to investigate multi-modality treatment combinations for aggressive Ewing sarcoma with STAG2 loss. The research addresses radiation therapy–induced immunobiological changes in Ewing tumors, focusing on epigenetic reprogramming and immune system activation to enhance radiation response in STAG2-deficient tumors. The recipient's...